In the GLP1-RAs RCTs (7 trials, 181 strokes, 46,097 participants), the risk of fatal hemorrhagic or ischemic stroke did not decrease with GLP1-RAs use (RR: 0.77, 95% CI [0.58, 1.03], p = 0.08) vs. non-GLP1-RAs use (fixed and random effect models; Supplementary Figures S10, S11). The gene discussed is GCG; the disease is Stroke.